# Alpheus Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alpheus-medical

- Industry: Biotechnology
- Headquarters: Chanhassen, US
- Website: www.alpheusmedical.com
- Total disclosed funding: $82M
- Latest round: Series B (May 15, 2025)
- Investors on record: 7

## About

Alpheus Medical Inc., based in the US, is dedicated to developing innovative sonodynamic therapy solutions targeting aggressive brain cancers, particularly glioblastoma multiforme, through a proprietary non-invasive ultrasound device.Founded in Chanhassen, US, Alpheus Medical Inc. operates in the neuro-oncology space, focusing on advanced treatment options for brain cancer. The company has conducted 3 deals, with their most recent deal occurring on May 15, 2025. Alpheus raised USD 52.00 mn in SERIES B funding, co-led by HealthQuest Capital and Samsara BioCapital, with previous investors Action Potential Venture Capital and OrbiMed Advisors also participating.Alpheus Medical, Inc. specializes in a pioneering sonodynamic therapy (SDT) platform aimed at treating aggressive brain cancers, particularly glioblastoma multiforme (GBM). The company's primary product features a proprietary non-invasive device that uses ultrasound to activate an FDA-approved drug designed to target cancer cells. This innovative treatment approach allows for the delivery of ultrasound across the entire diseased hemisphere of the brain, addressing tumor cells that extend beyond visible borders. The therapy is administered in an outpatient setting, with patients remaining awake and able to return home the same day. Alpheus Medical serves healthcare providers and institutions focused on neuro-oncology, operating primarily within the United States, with potential applications in global markets as the technology advances.Alpheus Medical generates revenue through transactions facilitated by its novel sonodynamic therapy platform. The company engages healthcare providers and cancer treatment centers directly, offering its proprietary device and associated drug for outpatient treatment of GBM. Transactions occur on a B2B basis, where medical facilities may integrate the therapy into their treatment offerings for patients diagnosed with brain tumors. Pricing structures for these services are based on treatment protocols involving the use of the device and the administered drug, supported by partnerships with organizations in the field of neuro-oncology to enhance market presence and facilitate broader adoption.In May 2025, Alpheus Medical Inc. raised USD 52.00 mn in SERIES B funding, which will be utilized to conduct a randomized Phase 2B clinical trial evaluating sonodynamic therapy in patients with newly diagnosed glioblastoma. The company aims to expand its innovative treatment solutions into new markets, with a focus on enhancing its presence in the neuro-oncology sector as the technology develops.

## Funding rounds

- Series B, May 15, 2025, $52M — OrbiMed Advisors, Action Potential Venture Capital, HealthQuest Capital, Samsara BioCapital
- Series A, Oct 25, 2022, $14M — OrbiMed Advisors, SV Health Investors, Action Potential Venture Capital, BrightEdge Ventures
- Series A, Nov 17, 2021, $16M — OrbiMed Advisors, SV Health Investors, Action Potential Venture Capital, BrightEdge Ventures, Brain Tumor Investment Fund

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Action Potential Venture Capital (https://capitalatlas.ai/funds/action-potential-venture-capital) — Series A, Series B
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series A
- Brain Tumor Investment Fund — Series A
- HealthQuest Capital (https://capitalatlas.ai/funds/healthquest-capital) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B